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Dear Editor,
Different lines of research have examined the role of neu-
rotrophins and oxidative stress on Bipolar Disorder (BD) and 
Schizophrenia (SZ).1-3
 
Nevertheless, the most extensively 
study so far seems to be the role of inflammation.4 Most of 
the studies of inflammation in psychiatric disorders have fo-
cused on inflammatory cytokines. The involvement of other 
components of the inflammatory response remains fairly 
obscure. The examination of different components of the 
inflammatory mechanism involved in these disorders might 
provide new possibilities of treatment. The serum comple-
ment system is one of the most important components of 
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humoral immunity; it consists of separate plasma proteins 
that react in a specific sequence with antigen-antibody 
complexes. The result of this sequence of reactions are 
increased vascular permeability, attraction of polymor-
phonuclear leukocites, enhancement of phagocytosis, and 
alterations in cell membrane that lead to lysis and cell 
death.5 The CS is an important part of the innate immune 
system, with the Complement 3 (C3) playing a central role 
in all pathways. Therefore, this study was designed to exam-
ine levels of two different components of the complement 
system: C3 and C4. Both components in euthymic patients 
with BD, and chronic stabilized patients with SZ in com-
parison to healthy controls. Methods have been described 
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Table 1 Characteristics of healthy controls and patients with Bipolar Disorder (BD) and, Schizophrenia (SZ)
Control group 
(n = 80)
BD euthymic
(n = 20)
SZ 
(n = 53)
p-value
Gender (M/F) a 32/48 8/12 40/13 < 0.0001*
Age, years a 40.7 (12.5) 46.6 (12.6) 39.9 (9.4) 0.115** 
Years of illness b - 12.0(16.3) 18.0(16.7) 0.026*** 
YMRS score b - 1.5 (6.5) - -
HAMD score b - 4.0 (4.5) - -
BPRS score b - - 12.0 (11.0) -
CGI score b - - 2.0 (1.0) -
Antipsychotic daily dose, In mg of chlorpromazine equivalents a - - 501.9 (218.1) -
C3(mg/dL) 162.6(50.1) 163.4(32.8) 190.3(43.6) 0.003** 
C4 (mg/dL) 38.4 (24.9) 33.1 (10.6) 40.3 (16.1) 0.352** 
YMRS: Young Mania Rating Scale; HAMD: Hamilton Depression Rating Scale; BPRS: Brief Psychiatry Rating Scale; CGI: clinical global impression. *Chi-Square; 
**One-way ANOVA; *** Mann-Whitney; a Shown as mean ± standard-deviation control/euthymic vs. SZ, p < 0.011.
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elsewhere.4 Table 1 shows sample’s characteristics. C3 was 
significantly higher in patients with SZ when compared 
to both controls (p < 0.011) or euthymic BD patients. C3 
levels were not different between controls and euthymic 
patients with BD (p = 0.998). There was no significant dif-
ference between serum levels of C4 among the three groups 
(p = 0.164). There was no correlation of antipsychotic dose 
and C3 (p = 0.613) or C4 (p = 0.668). Considering that our 
comparison involved patients in non-acute phases of illness 
(euthymic BD vs. chronic SZ), it provides additional evidence 
of a chronic immune activation and inflammatory syndrome 
in SZ, in accordance with previous studies.4 Nevertheless, 
these findings could also be explained by the longer duration 
of illness in the SZ group.2 We believe that a comparative 
assessment of the pathophysiological mechanisms in BD and 
SZ may provide interesting insights into the different roles 
played by such mechanisms in each disorder. Past compari-
sons have suggested different profiles of oxidative stress,3 
neurotrophins,1
 
and inflammatory cytokines4
 
in SZ and BD. 
While different lines of evidence suggest that, in BD, there 
is an episode-related deterioration pattern, and in SZ, this 
deterioration seems to be of a chronic nature, starting at 
the onset of the illness. Our results suggest activation of 
the CS in SZ, indicated by the increased levels of C3. This 
activation probably occurs through the alternative pathway, 
since there was no increase in C4 levels.
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